Evidence map›Paper›PMID 25465711›Full record

Trial reportEuropean radiology2015

Ultrasound-guided percutaneous injection to treat de Quervain's disease using three different techniques: a randomized controlled trial.

Davide Orlandi, Angelo Corazza, Emanuele Fabbro, Giulio Ferrero, Giuseppe Sabino, Giovanni Serafini, Enzo Silvestri, Luca Maria Sconfienza

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in European radiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 2 pooled it
3.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Tendon injections - upper extremity.Skeletal radiology · 2023
    Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Ultrasound-guided intervention in the ankle and foot.The British journal of radiology · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Davide OrlandiDepartment of Radiology, Genoa University, Via L.B. Alberti 4, 16100, Genova, Italy, theabo@libero.it.
Angelo Corazza
Emanuele Fabbro
Giulio Ferrero
Giuseppe Sabino
Giovanni Serafini
Enzo Silvestri
Luca Maria Sconfienza
University of Genoa · ITFederico II University Hospital · ITIRCCS Policlinico San Donato · ITOspedale Santa Corona · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo compare the six-month outcome of three different ultrasound-guided treatments for de Quervain's disease (DQD).

methodsWe prospectively treated 75 consecutive patients (51 females, 24 males, mean age ± standard deviation = 45.3 ± 9.8 years) with DQD. Patients' features (hand dominance, intraretinaculum septum, accessory tendons) were recorded. Visual analogue scale (VAS), reduced disability (quickDASH) score, and retinaculum thickness were evaluated at baseline and after one (excluding retinaculum thickness), three, and six months. Patients were randomized into three groups of 25 patients each treated under ultrasound guidance: Group A (1 ml methylprednisolone acetate; mean baseline thickness = 1.6 mm; mean baseline VAS = 6; mean baseline quickDASH = 55); Group B (1 ml methylprednisolone acetate +15-day delayed 2 ml saline 0.9 %; 1.4; 6; 56); Group C (1 ml methylprednisolone acetate +15-day delayed 2 ml low molecular weight hyaluronic acid; 1.7; 6; 55).

resultsAfter one month results were: Group A mean VAS = 2; mean quickDASH = 23; Group B 2; 22; Group C 2; 21. After three months results were: Group A retinaculum thickness = 0.7 mm; 3; 27); Group B 0.8 mm; 1; 25; Group C 0.5 mm; 1; 23. After six months results were: Group A 1.5 mm; 3; 51; Group B 1 mm; 2; 51; Group C 0.7 mm; 1; 26 (P < 0.001 for all vs. baseline). Patients' age, sex, hand dominance, presence of subcompartment dividing septum, and supernumerary tendons had no influence on outcome (P  ≥  0.177).

conclusionAddition of hyaluronic acid to ultrasound-guided injections of steroids to treat DQD seems to improve the outcome and to reduce the recurrence rate. KEY POINTS: • Ultrasound guidance allows for safe injection procedures to treat de Quervains' disease • Steroid injections allow prompt recovery in de Quervain's disease with short-term recurrence • Addition of hyaluronic acid allows recurrence rate reduction compared to simple steroid injections.

Indexed as

AdultAnti-Inflammatory AgentsDe Quervain DiseaseFemaleFollow-Up StudiesHumansHyaluronic AcidInjections, IntralesionalInjections, SubcutaneousMaleMethylprednisoloneMethylprednisolone AcetateMiddle AgedProspective StudiesRecurrenceSodium ChlorideAnti-Inflammatory AgentsHyaluronic AcidMethylprednisoloneMethylprednisolone AcetateSodium ChlorideViscosupplements

Identifiers

PMID25465711
OpenAlexW2049667937

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.